Conversely, the novel type 2 anti-CD20 mAb Obinutuzumab appears to overcome the refractoriness to anti-CD20 therapy in CLL carrying NOTCH1 mutations [89]. Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.